Status:
COMPLETED
Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Brief Summary
This is a descriptive observational open non-comparative study of the safety and efficacy of tiotropium inhalation capsule given at 18mcg once a day for 30 days among Korean patients with COPD. At Vis...
Detailed Description
Study Design:
Eligibility Criteria
Inclusion
- Older than 40 years old Diagnosed as COPD No Previous Spiriva administration No Contraindication for Spiriva according to the product label
Exclusion
- patients with history of hypersensitivity to atropine and its derivatives (e.g. ipratropium oxitropium or any component of this product).
Key Trial Info
Start Date :
March 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
3008 Patients enrolled
Trial Details
Trial ID
NCT00620516
Start Date
March 1 2004
Last Update
November 19 2013
Active Locations (71)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 1
Busan, South Korea
2
Boehringer Ingelheim Investigational Site 2
Busan, South Korea
3
Boehringer Ingelheim Investigational Site 3
Busan, South Korea
4
Boehringer Ingelheim Investigational Site 4
Busan, South Korea